329 related articles for article (PubMed ID: 19883729)
1. Prognostic utility of BRAF mutation in papillary thyroid cancer.
Xing M
Mol Cell Endocrinol; 2010 May; 321(1):86-93. PubMed ID: 19883729
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.
Xing M; Clark D; Guan H; Ji M; Dackiw A; Carson KA; Kim M; Tufaro A; Ladenson P; Zeiger M; Tufano R
J Clin Oncol; 2009 Jun; 27(18):2977-82. PubMed ID: 19414674
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
4. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW
J Clin Endocrinol Metab; 2005 Dec; 90(12):6373-9. PubMed ID: 16174717
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
7. Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAF(T1799A) mutation on fine-needle aspiration biopsy specimens: a prospective study of 814 thyroid FNAB patients.
Cañadas-Garre M; Becerra-Massare P; López de la Torre-Casares M; Villar-del Moral J; Céspedes-Mas S; Vílchez-Joya R; Muros-de Fuentes T; García-Calvente C; Piédrola-Maroto G; López-Nevot MA; Montes-Ramírez R; Llamas-Elvira JM
Ann Surg; 2012 May; 255(5):986-92. PubMed ID: 22504197
[TBL] [Abstract][Full Text] [Related]
8. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
[TBL] [Abstract][Full Text] [Related]
9. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.
Alzahrani AS; Xing M
Endocr Relat Cancer; 2013 Feb; 20(1):13-22. PubMed ID: 23132792
[TBL] [Abstract][Full Text] [Related]
10. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
12. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT; Lee CH
J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases.
Shen G; Kou Y; Liu B; Huang R; Kuang A
Clin Nucl Med; 2018 Jul; 43(7):e215-e219. PubMed ID: 29762246
[TBL] [Abstract][Full Text] [Related]
15. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
16. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.
Yip L; Nikiforova MN; Carty SE; Yim JH; Stang MT; Tublin MJ; Lebeau SO; Hodak SP; Ogilvie JB; Nikiforov YE
Surgery; 2009 Dec; 146(6):1215-23. PubMed ID: 19958951
[TBL] [Abstract][Full Text] [Related]
17. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.
Lassalle S; Hofman V; Ilie M; Butori C; Bozec A; Santini J; Vielh P; Hofman P
Curr Med Chem; 2010; 17(17):1839-50. PubMed ID: 20345340
[TBL] [Abstract][Full Text] [Related]
19. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.
Guan H; Ji M; Bao R; Yu H; Wang Y; Hou P; Zhang Y; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2009 May; 94(5):1612-7. PubMed ID: 19190105
[TBL] [Abstract][Full Text] [Related]
20. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]